25.85
-0.51(-1.93%)
Currency In USD
| Previous Close | 26.36 |
| Open | 26.49 |
| Day High | 26.63 |
| Day Low | 25.8 |
| 52-Week High | 31.77 |
| 52-Week Low | 11.13 |
| Volume | 1.11M |
| Average Volume | 2.33M |
| Market Cap | 3.17B |
| PE | -76.03 |
| EPS | -0.34 |
| Moving Average 50 Days | 28.16 |
| Moving Average 200 Days | 19.05 |
| Change | -0.51 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $1,185.78 as of January 18, 2026 at a share price of $25.85. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 5 years ago, it would be worth $900.07 as of January 18, 2026 at a share price of $25.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidraden
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
GlobeNewswire Inc.
Dec 08, 2025 9:00 PM GMT
Amit Munshi Amit Munshi, Arcutis Biotherapeutics WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov.